{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T05:21:24Z","timestamp":1767158484316,"version":"3.48.0"},"reference-count":188,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astra Zeneca","award":["na"],"award-info":[{"award-number":["na"]}]},{"name":"Gilead Sciences","award":["na"],"award-info":[{"award-number":["na"]}]},{"name":"Eli Lilly","award":["na"],"award-info":[{"award-number":["na"]}]},{"DOI":"10.13039\/100030841","name":"Exact Sciences","doi-asserted-by":"crossref","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100030841","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009945","name":"Merck","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019484","name":"Merit Medical","doi-asserted-by":"crossref","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100019484","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008272","name":"Novartis","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"Hoffmann-La Roche","doi-asserted-by":"crossref","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MDPI","award":["na"],"award-info":[{"award-number":["na"]}]},{"DOI":"10.13039\/100008894","name":"Stryker","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100008894","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beone","award":["na"],"award-info":[{"award-number":["na"]}]},{"DOI":"10.13039\/100015160","name":"Hologic","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100015160","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The 2025 Canadian Breast Cancer Symposium (CBCS) brought together patients, clinicians and researchers from across Canada to discuss advances shaping personalized breast cancer care. Key updates in systemic therapy highlighted expanding treatment options, including CDK4\/6 inhibitors, oral SERDs, PI3K\/AKT-targeted therapies, and antibody\u2013drug conjugates across early and metastatic settings. Radiation oncology sessions emphasized treatment de-escalation, featuring evidence for ultra-hypofractionation, selective omission of nodal irradiation, and stereotactic strategies to manage oligoprogression. Surgical presentations focused on reducing morbidity through tailored axillary management and emerging techniques to prevent lymphedema. Advances in the management of central nervous system metastases underscored the growing synergy between stereotactic radiotherapy and CNS-active systemic therapies. Informed by patient testimony and advocacy perspectives, experts reflected on persistent gaps in diagnosis, access, and survivorship that shape priorities for future improvements. Together, these insights outline key directions that help to refine clinical practice and guide future research.<\/jats:p>","DOI":"10.3390\/curroncol33010015","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T23:54:36Z","timestamp":1766966076000},"page":"15","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Canadian Breast Cancer Symposium 2025: Meeting Report"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-318X","authenticated-orcid":false,"given":"Christine","family":"Brezden-Masley","sequence":"first","affiliation":[{"name":"Marvelle Koffler Breast Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Nixon","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, University of Calgary, Calgary, AB T2N 4Z6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Koch","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-0316","authenticated-orcid":false,"given":"Amanda","family":"Roberts","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Boileau","sequence":"additional","affiliation":[{"name":"Jewish General Hospital, Montreal, QC H3T 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Lynn","family":"Quan","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, University of Calgary, Calgary, AB T2N 4Z6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ","family":"DeCoteau","sequence":"additional","affiliation":[{"name":"Rethink Breast Cancer, Toronto, ON M4M 3G3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulin D.","family":"Cil","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1470-2045(24)00661-2","article-title":"Single-Modality Endocrine Therapy versus Radiotherapy After Breast-Conserving Surgery in Women Aged 70 Years and Older with Luminal A-like Early Breast Cancer (EUROPA): A Preplanned Interim Analysis of a Phase 3, Non-Inferiority, Randomised Trial","volume":"26","author":"Meattini","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"110849","DOI":"10.1016\/j.radonc.2025.110849","article-title":"Early Toxicity of Moderately Hypofractionated Radiation Therapy in Breast Cancer Patients Receiving Locoregional Irradiation: First Results of the UNICANCER HypoG-01 Phase III Trial","volume":"207","author":"Brion","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2500031","DOI":"10.1200\/OA-25-00031","article-title":"Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor\u2013Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial","volume":"2","author":"David","year":"2025","journal-title":"JCO Oncol. Adv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","article-title":"Association between Risk-Reducing Surgeries and Survival in Young BRCA Carriers with Breast Cancer: An International Cohort Study","volume":"26","author":"Blondeaux","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary Surgery in Breast Cancer\u2014Primary Results of the INSEMA Trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/jama.2024.26698","article-title":"Active Monitoring with or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial","volume":"333","author":"Hwang","year":"2025","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1200\/JCO.2025.43.16_suppl.1003","article-title":"INAVO120: Phase III Trial Final Overall Survival (OS) Analysis of First-Line Inavolisib (INAVO)\/Placebo (PBO) + Palbociclib (PALBO) + Fulvestrant (FULV) in Patients (Pts) with PIK3CA-Mutated, Hormone Receptor-Positive (HR+), HER2-Negative (HER2\u2013), Endocrine-Resistant Advanced Breast Cancer (aBC)","volume":"43","author":"Turner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"LBA1005","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1005","article-title":"A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER2-Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4\/6 Inhibitor and Aromatase Inhibitor: The CCTG\/BCT MA.40\/FINER Study (NCT04650581)","volume":"43","author":"Chia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1000","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER-Positive\/Human Epidermal Growth Factor Receptor 2 (HER2)\u2013Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study","volume":"43","author":"Hamilton","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or Without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.2025.43.16_suppl.1013","article-title":"Exploratory Biomarker Analysis of Trastuzumab Deruxtecan (T-DXd) vs Physician\u2019s Choice of Chemotherapy (TPC) in HER2-Low\/Ultralow, Hormone Receptor\u2013Positive (HR+) Metastatic Breast Cancer (mBC) in DESTINY-Breast06 (DB-06)","volume":"43","author":"Dent","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"LBA109","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1\u2013Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results from the Randomized Phase 3 ASCENT-04\/KEYNOTE-D19 Study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"LBA1008","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1008","article-title":"Trastuzumab Deruxtecan (T-DXd) + Pertuzumab (P) vs Taxane + Trastuzumab + Pertuzumab (THP) for First-Line (1L) Treatment of Patients (Pts) with Human Epidermal Growth Factor Receptor 2\u2013Positive (HER2+) Advanced\/Metastatic Breast Cancer (a\/mBC): Interim Results from DESTINY-Breast09","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"unstructured":"Schultz, A. (2024, January 10\u201313). General Session 2 Features Practice-Changing Findings, Including Late-Breaking Data from PATINA Trial. Proceedings of the SABCS Meeting News 2024, San Antonio, TX, USA.","key":"ref_15"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab Deruxtecan in HER2-Positive Advanced Breast Cancer with or Without Brain Metastases: A Phase 3b\/4 Trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"unstructured":"(2025, July 08). Cancer Today. Available online: https:\/\/gco.iarc.who.int\/today\/.","key":"ref_17"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/s41591-022-02109-2","article-title":"Global and Regional Estimates of Orphans Attributed to Maternal Cancer Mortality in 2020","volume":"28","author":"Guida","year":"2022","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"423562","DOI":"10.1155\/2012\/423562","article-title":"Improving Outcomes from Breast Cancer in a Low-Income Country: Lessons from Bangladesh","volume":"2012","author":"Story","year":"2012","journal-title":"Int. J. Breast Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/cncr.32888","article-title":"Designing a Resource-stratified, Phased Implementation Strategy for Breast Health Care Services in India","volume":"126","author":"Kumar","year":"2020","journal-title":"Cancer"},{"unstructured":"(2025, September 29). Operational Approach Based on 3 Pillars. Available online: https:\/\/www.who.int\/initiatives\/global-breast-cancer-initiative\/operational-approach-based-on-3-pillars.","key":"ref_21"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative, High-Risk Early Breast Cancer: Results from a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes","volume":"42","author":"Rastogi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A Phase III Trial of Adjuvant Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Patients with HR-Positive\/HER2-Negative Early Breast Cancer: Final Invasive Disease-Free Survival Results from the NATALEE Trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.2025.43.16_suppl.517","article-title":"The TRADE Study: A Phase 2 Trial to Assess the Tolerability of Abemaciclib Dose Escalation in Early-Stage HR+\/HER2- Breast Cancer","volume":"43","author":"Mayer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2025.43.16_suppl.505","article-title":"15-Year Outcomes for Women with Premenopausal Hormone Receptor-Positive Early Breast Cancer (BC) in the SOFT and TEXT Trials Assessing Benefits from Adjuvant Exemestane (E) + Ovarian Function Suppression (OFS) or Tamoxifen (T)+OFS","volume":"43","author":"Francis","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant Nivolumab and Chemotherapy in Early Estrogen Receptor-Positive Breast Cancer: A Randomized Phase 3 Trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and Chemotherapy in High-Risk, Early-Stage, ER+\/HER2\u2212 Breast Cancer: A Randomized Phase 3 Trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized Phase II Trial of Endocrine Therapy with or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4\/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4\/6 Inhibition: Results from the Phase III postMONARCH Trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-Generation Oral SERD, versus Fulvestrant in Post-Menopausal Women with Oestrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (SERENA-2): A Multi-Dose, Open-Label, Randomised, Phase 2 Trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4\/6 Inhibitor and in Clinical Subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan After Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor\u2013Positive Human Epidermal Growth Factor Receptor 2\u2013Negative Breast Cancer: Primary Results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall Survival with Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"LBA1004","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1004","article-title":"SACI-IO HR+: A Randomized Phase II Trial of Sacituzumab Govitecan with or Without Pembrolizumab in Patients with Metastatic Hormone Receptor-Positive\/HER2-Negative Breast Cancer","volume":"42","author":"Kim","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"P5-03-11","DOI":"10.1158\/1557-3265.SABCS24-P5-03-11","article-title":"Abstract P5-03-11: DEMETHER: A Single-Arm Phase II Trial to Evaluate the Efficacy & Safety of Subcutaneous Pertuzumab & Trastuzumab Maintenance After Induction Treatment w\/ Trastuzumab Deruxtecan (T-DXd) for Previously Untreated HER2-Positive Advanced Breast Cancer","volume":"31","author":"Antonarelli","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.3390\/curroncol31110484","article-title":"Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting","volume":"31","author":"Manna","year":"2024","journal-title":"Curr. Oncol."},{"unstructured":"Daiichi Sankyo (2025, September 29). A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04622319.","key":"ref_41"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17588359241248336","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: A Randomized Phase III Global Trial of Datopotamab Deruxtecan \u00b1 Durvalumab in Patients with Triple-Negative Breast Cancer and Residual Invasive Disease at Surgical Resection After Neoadjuvant Therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"unstructured":"Merck Sharp & Dohme LLC (2025, September 29). A Phase 3, Randomized, Open-Label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician\u2019s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06393374.","key":"ref_44"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","article-title":"OptimICE-RD: Sacituzumab Govitecan + Pembrolizumab vs Pembrolizumab (\u00b1 Capecitabine) for Residual Triple-Negative Breast Cancer","volume":"20","author":"Tolaney","year":"2024","journal-title":"Future Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"unstructured":"Merck Sharp & Dohme LLC (2025, September 29). A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin\/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-Low Positive\/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06966700.","key":"ref_47"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17588359251316176","DOI":"10.1177\/17588359251316176","article-title":"TROPION-Breast04: A Randomized Phase III Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab Followed by Adjuvant Durvalumab versus Standard of Care in Patients with Treatment-Na\u00efve Early-Stage Triple Negative or HR-Low\/HER2- Breast Cancer","volume":"17","author":"McArthur","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jama.281.17.1586","article-title":"Intensive vs Clinical Follow-up After Treatment of Primary Breast Cancer: 10-Year Update of a Randomized Trial. National Research Council Project on Breast Cancer Follow-Up","volume":"281","author":"Palli","year":"1999","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2012.45.9859","article-title":"Breast Cancer Follow-up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"31","author":"Khatcheressian","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early Breast Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2025.43.16_suppl.1009","article-title":"Circulating Tumor DNA, Pathologic Response After Neoadjuvant Therapy, and Survival: First Results from TBCRC 040 (the PREDICT-DNA Trial)","volume":"43","author":"Hunter","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"dju261","DOI":"10.1093\/jnci\/dju261","article-title":"Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer","volume":"106","author":"Coldman","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/ijc.31950","article-title":"Breast Cancer-Specific Survival by Clinical Subtype After 7 Years Follow-up of Young and Elderly Women in a Nationwide Cohort","volume":"144","author":"Johansson","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1002\/cncr.33846","article-title":"Age Distributions of Breast Cancer Diagnosis and Mortality by Race and Ethnicity in US Women","volume":"127","author":"Hendrick","year":"2021","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e221785","DOI":"10.1148\/radiol.221785","article-title":"Supplemental Breast Cancer Screening in Women with Dense Breasts and Negative Mammography: A Systematic Review and Meta-Analysis","volume":"306","author":"Hussein","year":"2023","journal-title":"Radiology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2020.0572","article-title":"Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women with Dense Breasts Undergoing Screening","volume":"323","author":"Comstock","year":"2020","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejrad.2017.10.001","article-title":"Comparison of Screening CEDM and MRI for Women at Increased Risk for Breast Cancer: A Pilot Study","volume":"97","author":"Jochelson","year":"2017","journal-title":"Eur. J. Radiol."},{"doi-asserted-by":"crossref","unstructured":"START Trialists\u2019 Group, Bentzen, S.M., Agrawal, R.K., Aird, E.G.A., Barrett, J.M., Barrett-Lee, P.J., Bentzen, S.M., Bliss, J.M., Brown, J., and Dewar, J.A. (2008). The UK Standardisation of Breast Radiotherapy (START) Trial B of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: A Randomised Trial. Lancet, 371, 1098\u20131107.","key":"ref_59","DOI":"10.1016\/S0140-6736(08)60348-7"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"110915","DOI":"10.1016\/j.radonc.2025.110915","article-title":"Patient- and Clinician-Assessed Five-Year Normal Tissue Effects Following One-Week versus Three-Week Axillary Radiotherapy for Breast Cancer: Results from the Phase III FAST-Forward Trial Randomised Nodal Sub-Study","volume":"207","author":"Brunt","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-Conserving Surgery with or Without Irradiation in Early Breast Cancer","volume":"388","author":"Kunkler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMoa2302344","article-title":"Omitting Radiotherapy After Breast-Conserving Surgery in Luminal A Breast Cancer","volume":"389","author":"Whelan","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.23.02270","article-title":"Omission of Radiotherapy After Breast-Conserving Surgery for Women with Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA","volume":"42","author":"Jagsi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","article-title":"Omitting Regional Nodal Irradiation After Response to Neoadjuvant Chemotherapy","volume":"392","author":"Mamounas","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","article-title":"Eliminating Breast Surgery for Invasive Breast Cancer in Exceptional Responders to Neoadjuvant Systemic Therapy: A Multicentre, Single-Arm, Phase 2 Trial","volume":"23","author":"Kuerer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2025.0207","article-title":"Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial","volume":"11","author":"Kuerer","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamasurg.2025.1072","article-title":"Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial","volume":"160","author":"Basik","year":"2025","journal-title":"JAMA Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e204103","DOI":"10.1001\/jamasurg.2020.4103","article-title":"Accuracy of Post\u2013Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer","volume":"155","author":"Tasoulis","year":"2020","journal-title":"JAMA Surg."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamasurg.2024.5913","article-title":"De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer","volume":"160","author":"Cabioglu","year":"2025","journal-title":"JAMA Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1245\/s10434-025-16973-y","article-title":"Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial","volume":"32","author":"Boughey","year":"2025","journal-title":"Ann. Surg. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Weber, E., Carmona-Gonzalez, C.A., Boucher, M., Eisen, A., Laing, K., Melvin, J., Schrader, K.A., Sehdev, S., Wong, S.M., and Gelmon, K.A. (2025). Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to Action. Curr. Oncol., 32.","key":"ref_72","DOI":"10.20944\/preprints202503.2053.v1"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"GS02-04","DOI":"10.1158\/1538-7445.SABCS23-GS02-04","article-title":"Abstract GS02-04: Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival","volume":"84","author":"Metcalfe","year":"2024","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Patients with Germline Pathogenic Variants in BRCA1\/2 and High-Risk, Early Breast Cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results from Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27","volume":"30","author":"Mamounas","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","article-title":"Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?","volume":"25","author":"Moo","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1245\/s10434-021-09910-2","article-title":"Is Residual Nodal Disease at Axillary Dissection Associated with Tumor Subtype in Patients with Low Volume Sentinel Node Metastasis After Neoadjuvant Chemotherapy?","volume":"28","author":"Moo","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer (EORTC 10981-22023 AMAROS): A Randomised, Multicentre, Open-Label, Phase 3 Non-Inferiority Trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases","volume":"390","author":"Szulkin","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"RF2-01","DOI":"10.1158\/1557-3265.SABCS24-RF2-01","article-title":"Abstract RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial","volume":"31","author":"Boughey","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.suronc.2006.11.003","article-title":"Lymphedema Following Axillary Lymph Node Dissection for Breast Cancer","volume":"15","author":"Sakorafas","year":"2006","journal-title":"Surg. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/lrb.2011.0011","article-title":"Surgical Management of Lymphedema: Past, Present, and Future","volume":"9","author":"Mehrara","year":"2011","journal-title":"Lymphat. Res. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMcp1803290","article-title":"Lymphedema After Breast Cancer Treatment","volume":"379","author":"Rockson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1245\/s10434-008-0270-y","article-title":"Lymphedema Microsurgical Preventive Healing Approach: A New Technique for Primary Prevention of Arm Lymphedema After Mastectomy","volume":"16","author":"Boccardo","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1055\/s-0044-1785680","article-title":"Lymphovenous Bypass for Immediate Lymphatic Reconstruction in Breast Cancer Patients Undergoing Axillary Lymph Node Dissection: Minimizing the Risk of Upper Extremity Lymphedema","volume":"40","author":"Churchill","year":"2024","journal-title":"J. Reconstr. Microsurg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/SLA.0000000000005952","article-title":"Efficacy of Immediate Lymphatic Reconstruction to Decrease Incidence of Breast Cancer-Related Lymphedema: Preliminary Results of Randomized Controlled Trial","volume":"278","author":"Coriddi","year":"2023","journal-title":"Ann. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/PRS.0000000000009857","article-title":"Lymphatic Microsurgical Preventive Healing Approach for the Primary Prevention of Lymphedema: A 4-Year Follow-Up","volume":"151","author":"Levy","year":"2023","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.amjsurg.2009.06.008","article-title":"Scientific Impact Award: Axillary Reverse Mapping (ARM) to Identify and Protect Lymphatics Draining the Arm during Axillary Lymphadenectomy","volume":"198","author":"Boneti","year":"2009","journal-title":"Am. J. Surg."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.21037\/gs-21-186","article-title":"The Effectiveness of Axillary Reverse Mapping in Preventing Breast Cancer-Related Lymphedema: A Meta-Analysis Based on Randomized Controlled Trials","volume":"10","author":"Guo","year":"2021","journal-title":"Gland Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/SLA.0000000000002827","article-title":"Evaluation of Simplified Lymphatic Microsurgical Preventing Healing Approach (S-LYMPHA) for the Prevention of Breast Cancer-Related Clinical Lymphedema After Axillary Lymph Node Dissection","volume":"270","author":"Ozmen","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J. Clin. Oncol."},{"unstructured":"Executive Committee (2016). The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology. Lymphology, 49, 170\u2013184.","key":"ref_93"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.21.01681","article-title":"Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis","volume":"40","author":"Rafn","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102441","DOI":"10.1016\/j.eclinm.2024.102441","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) Clinical Practice Guidance for the Prevention of Breast Cancer-Related Arm Lymphoedema (BCRAL): International Delphi Consensus-Based Recommendations","volume":"68","author":"Wong","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e2455383","DOI":"10.1001\/jamanetworkopen.2024.55383","article-title":"External Validation of a 5-Factor Risk Model for Breast Cancer\u2013Related Lymphedema","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e2024373","DOI":"10.1001\/jamanetworkopen.2020.24373","article-title":"Development and Validation of a Risk Model for Breast Cancer-Related Lymphedema","volume":"3","author":"Kwan","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1078-0432.CCR-23-1789","article-title":"Sensitive MRD Detection from Lymphatic Fluid After Surgery in HPV-Associated Oropharyngeal Cancer","volume":"30","author":"Earland","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1002\/onco.13734","article-title":"Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer","volume":"26","author":"Pramod","year":"2021","journal-title":"Oncologist"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10549-022-06572-w","article-title":"Invasive Lobular Carcinoma: An Understudied Emergent Subtype of Breast Cancer","volume":"193","author":"Mouabbi","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1200\/JCO.2015.64.0334","article-title":"Genomic Characterization of Primary Invasive Lobular Breast Cancer","volume":"34","author":"Desmedt","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2021.11.017","article-title":"Differences in Sensitivity to Neoadjuvant Chemotherapy Among Invasive Lobular and Ductal Carcinoma of the Breast and Implications on Surgery\u2013A Systematic Review and Meta-Analysis","volume":"61","author":"Davey","year":"2022","journal-title":"Breast"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1200\/JCO.2023.41.16_suppl.554","article-title":"SEER Analysis of 9-Year Breast Cancer Specific Mortality (BCSM) in Patients (Pts) with Invasive Lobular Breast Cancer (ILC) Assessed by the 21-Gene Breast Recurrence Score Assay","volume":"41","author":"Geyer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41416-021-01690-6","article-title":"The Impact of Anthracyclines in Intermediate and High-Risk HER2-Negative Early Breast Cancer\u2014A Pooled Analysis of the Randomised Clinical Trials PlanB and SUCCESS C","volume":"126","author":"Janni","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2015.60.8133","article-title":"Relative Effectiveness of Letrozole Compared with Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial","volume":"33","author":"Mallon","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.014","article-title":"Outcomes in Women with Invasive Ductal or Invasive Lobular Early Stage Breast Cancer Treated with Anastrozole or Exemestane in CCTG (NCIC CTG) MA.27","volume":"90","author":"Sudan","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"103257","DOI":"10.1016\/j.esmoop.2024.103257","article-title":"236P Survival Outcomes of Patients (Pts) with Metastatic Lobular Breast Cancer (mLBC) Receiving Cyclin-Dependent Kinase 4\/6 Inhibitors (CDK4\/6i) and Endocrine Therapy (ET): A Retrospective Analysis","volume":"9","author":"Castellano","year":"2024","journal-title":"ESMO Open"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/jnci\/djac157","article-title":"Clinicopathological Features and Outcomes Comparing Patients with Invasive Ductal and Lobular Breast Cancer","volume":"114","author":"Oesterreich","year":"2022","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1245\/s10434-021-10455-7","article-title":"Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making","volume":"28","author":"Cocco","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.soc.2017.07.005","article-title":"Lobular Breast Cancer: Different Disease, Different Algorithms?","volume":"27","author":"Mamtani","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.3390\/curroncol30070463","article-title":"Preoperative Breast Magnetic Resonance Imaging: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline","volume":"30","author":"Muradali","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2967\/jnumed.115.161455","article-title":"Comparison of 18F-FDG PET\/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma","volume":"56","author":"Hogan","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.amjsurg.2021.05.021","article-title":"Positive Margins After Mastectomy in Patients with Invasive Lobular Carcinoma of the Breast: Incidence and Management Strategies","volume":"223","author":"Hewitt","year":"2022","journal-title":"Am. J. Surg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-022-06522-6","article-title":"A Canadian National Guideline on the Neoadjuvant Treatment of Invasive Breast Cancer, Including Patient Assessment, Systemic Therapy, and Local Management Principles","volume":"193","author":"Gandhi","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"doi-asserted-by":"crossref","unstructured":"Pate, L., Desmedt, C., Metzger, O., Burgess Hutcheson, L., Turner, C., Freeney, S., and Oesterreich, S. (2021). How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research. Cancers, 13.","key":"ref_115","DOI":"10.3390\/cancers13133094"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41379-022-01135-2","article-title":"Results of a Worldwide Survey on the Currently Used Histopathological Diagnostic Criteria for Invasive Lobular Breast Cancer","volume":"35","author":"Christgen","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100497","DOI":"10.1016\/j.modpat.2024.100497","article-title":"Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations from the European Lobular Breast Cancer Consortium","volume":"37","author":"Koorman","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41523-024-00661-3","article-title":"International Survey on Invasive Lobular Breast Cancer Identifies Priority Research Questions","volume":"10","author":"Oesterreich","year":"2024","journal-title":"npj Breast Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1007\/s00330-024-11338-7","article-title":"Preoperative Breast MRI Reduces Reoperations for Unilateral Invasive Lobular Carcinoma: A Patient-Matched Analysis from the MIPA Study","volume":"35","author":"Cozzi","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1007\/s00330-025-11502-7","article-title":"Preoperative Estimation of the Pathological Breast Tumor Size in Architectural Distortions: A Comparison of DM, DBT, US, CEM, and MRI","volume":"35","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"104202","DOI":"10.1016\/j.labinv.2025.104202","article-title":"Histopathological Insights into Metastatic Breast Cancer Gained from Rapid Autopsies","volume":"105","author":"Zels","year":"2025","journal-title":"Lab. Investig."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"115222","DOI":"10.1016\/j.ejca.2025.115222","article-title":"Survival Outcomes for Patients with Invasive Lobular Cancer by MammaPrint: Results from the MINDACT Phase III Trial","volume":"217","author":"Cardoso","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41523-019-0113-y","article-title":"LobSig Is a Multigene Predictor of Outcome in Invasive Lobular Carcinoma","volume":"5","author":"Lal","year":"2019","journal-title":"npj Breast Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2024.42.16_suppl.1044","article-title":"The Multiomic Tumor Microenvironment Landscape of Invasive Lobular Carcinoma of the Breast","volume":"42","author":"Mouabbi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"104746","DOI":"10.1016\/j.esmoop.2025.104746","article-title":"192MO Primary Endpoint of ROSALINE: A Phase II Neoadjuvant Study of Endocrine Therapy (ET) and Entrectinib in Invasive Lobular Breast Carcinoma (ILBC)","volume":"10","author":"Agostinetto","year":"2025","journal-title":"ESMO Open"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.annonc.2025.03.010","article-title":"Final Survival Results from the PENELOPE-B Trial Investigating Palbociclib versus Placebo for Patients with High-Risk HR+\/HER2\u2212 Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy","volume":"36","author":"Loibl","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2015.11.002","article-title":"Prevalence of Sexual Dysfunction After Risk-Reducing Salpingo-Oophorectomy","volume":"140","author":"Tucker","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ygyno.2024.10.007","article-title":"What Happens After Menopause? (WHAM): A Prospective Controlled Study of Vasomotor Symptoms and Menopause-Related Quality of Life 24 Months After Premenopausal Risk-Reducing Salpingo-Oophorectomy (RRSO)","volume":"191","author":"Hickey","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/curroncol29030149","article-title":"Gynecologic Symptoms Among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study","volume":"29","author":"Moskalewicz","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AOG.0000000000001621","article-title":"Sexual Health in Women Affected by Cancer: Focus on Sexual Pain","volume":"128","author":"Coady","year":"2016","journal-title":"Obs. Gynecol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajog.2024.10.054","article-title":"Vaginal Estrogen Use in Breast Cancer Survivors: A Systematic Review and Meta-Analysis of Recurrence and Mortality Risks","volume":"232","author":"Beste","year":"2025","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jsxm.2022.05.141","article-title":"Beneficial Effects of Intrarosa\u00ae (Vaginal Prasterone) on the Vaginal Histology of Women with VVA Treated or Not with Aromatase Inhibitors: A Breakthrough in the Understanding of the Role of Androgens in Vaginal Health","volume":"19","author":"Bouchard","year":"2022","journal-title":"J. Sex. Med."},{"unstructured":"Senshio|European Medicines Agency (EMA) (2025, September 16). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/senshio.","key":"ref_133"},{"unstructured":"(2025, September 16). Summary Basis of Decision for Osphena. Available online: https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD00564.","key":"ref_134"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(21)00183-2","article-title":"The Definition of Pregnancy-Associated Breast Cancer Is Outdated and Should No Longer Be Used","volume":"22","author":"Amant","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.annonc.2023.08.001","article-title":"ESMO Expert Consensus Statements on the Management of Breast Cancer during Pregnancy (PrBC)","volume":"34","author":"Loibl","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/annonc\/mdu140","article-title":"Optimizing Anticancer Drug Treatment in Pregnant Cancer Patients: Pharmacokinetic Analysis of Gestation-Induced Changes for Doxorubicin, Epirubicin, Docetaxel and Paclitaxel","volume":"25","author":"Heyns","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","article-title":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable","volume":"51","author":"Campbell","year":"2019","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2502760","article-title":"Structured Exercise After Adjuvant Chemotherapy for Colon Cancer","volume":"393","author":"Courneya","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"101064","DOI":"10.1016\/j.jshs.2025.101064","article-title":"Effects of Aerobic or Resistance Exercise during Neoadjuvant Chemotherapy on Tumor Response and Therapy Completion in Women with Breast Cancer: The Randomized Controlled BENEFIT Trial","volume":"14","author":"Schmidt","year":"2025","journal-title":"J. Sport Health Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10549-008-0023-4","article-title":"Impact on Survival of Early Detection of Isolated Breast Recurrences After the Primary Treatment for Breast Cancer: A Meta-Analysis","volume":"114","author":"Lu","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.2011.188","article-title":"Accuracy and Outcomes of Screening Mammography in Women with a Personal History of Early-Stage Breast Cancer","volume":"305","author":"Houssami","year":"2011","journal-title":"JAMA"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2016.1708","article-title":"Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts","volume":"315","author":"Rafferty","year":"2016","journal-title":"JAMA"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s40064-015-1158-5","article-title":"Breast Magnetic Resonance Imaging (MRI) Surveillance in Breast Cancer Survivors","volume":"4","author":"Weinstock","year":"2015","journal-title":"Springerplus"},{"doi-asserted-by":"crossref","unstructured":"Fonseca, M.M., Alhassan, T., Nisha, Y., Koszycki, D., Schwarz, B.A., Segal, R., Arnaout, A., Ramsay, T., Lau, J., and Seely, J.M. (2022). Randomized Trial of Surveillance with Abbreviated MRI in Women with a Personal History of Breast Cancer\u2013 Impact on Patient Anxiety and Cancer Detection. BMC Cancer, 22.","key":"ref_145","DOI":"10.1186\/s12885-022-09792-x"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10549-023-06916-0","article-title":"Contrast Enhanced Mammography in Breast Cancer Surveillance","volume":"199","author":"Elder","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"doi-asserted-by":"crossref","unstructured":"Gluskin, J., Rossi Saccarelli, C., Avendano, D., Marino, M.A., Bitencourt, A.G.V., Pilewskie, M., Sevilimedu, V., Sung, J.S., Pinker, K., and Jochelson, M.S. (2020). Contrast-Enhanced Mammography for Screening Women After Breast Conserving Surgery. Cancers, 12.","key":"ref_147","DOI":"10.3390\/cancers12123495"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jama.2012.388","article-title":"Detection of Breast Cancer with Addition of Annual Screening Ultrasound or a Single Screening MRI to Mammography in Women with Elevated Breast Cancer Risk","volume":"307","author":"Berg","year":"2012","journal-title":"JAMA"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/08465371251318578","article-title":"Cancers Detected on Supplemental Breast Ultrasound in Women with Dense Breasts: Update from a Canadian Centre","volume":"76","author":"Gordon","year":"2025","journal-title":"Can. Assoc. Radiol. J."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","article-title":"Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Pre-Planned Feasibility Substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101)","volume":"60","author":"Weber","year":"2021","journal-title":"Breast"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e2452821","DOI":"10.1001\/jamanetworkopen.2024.52821","article-title":"Cost-Effectiveness of Breast Cancer Screening Using Digital Mammography in Canada","volume":"8","author":"Wilkinson","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1245\/s10434-016-5446-2","article-title":"The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis","volume":"23","author":"Marinovich","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2016.68.3573","article-title":"Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ","volume":"34","author":"Morrow","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.wnsx.2023.100170","article-title":"Stereotactic Radiosurgery versus Whole-Brain Radiotherapy after Resection of Solitary Brain Metastasis: A Systematic Review and Meta-Analysis","volume":"18","author":"Vlachos","year":"2023","journal-title":"World Neurosurg. X"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","article-title":"A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and International Stereotactic Radiosurgery Society Recommendations","volume":"118","author":"Vellayappan","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-022-04055-y","article-title":"Trastuzumab Emtansine Increases the Risk of Stereotactic Radiosurgery-Induced Radionecrosis in HER2 + Breast Cancer","volume":"159","author":"Chen","year":"2022","journal-title":"J. Neuro-Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/neuros\/nyx522","article-title":"Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline","volume":"83","author":"Chao","year":"2018","journal-title":"Neurosurgery"},{"key":"ref_160","first-page":"CD006121","article-title":"Whole Brain Radiation Therapy (WBRT) Alone versus WBRT and Radiosurgery for the Treatment of Brain Metastases","volume":"9","author":"Patil","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"100502","DOI":"10.1016\/j.medj.2024.08.001","article-title":"The DEBBRAH Trial: Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Breast Cancer Patients with Leptomeningeal Carcinomatosis","volume":"6","author":"Cortez","year":"2025","journal-title":"Med"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2024.08.2347","article-title":"A Pooled Analysis of Trastuzumab Deruxtecan in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer with Brain Metastases","volume":"35","author":"Curigliano","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs Placebo, Both in Combination with Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients with Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2018.0813","article-title":"Implications of Screening for Brain Metastases in Patients with Breast Cancer and Non\u2013Small Cell Lung Cancer","volume":"4","author":"Cagney","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"104558","DOI":"10.1016\/j.breast.2025.104558","article-title":"Brain Imaging Screening in Metastatic Breast Cancer: Patients\u2019 and Physicians\u2019 Perspectives","volume":"84","author":"Matos","year":"2025","journal-title":"Breast"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1200\/JCO-25-00356","article-title":"Brain Imaging Surveillance for Patients with Metastatic Breast Cancer: A Randomized Clinical Trial Is Required to Guide Practice","volume":"43","author":"Jerzak","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdg300","article-title":"Occult Central Nervous System Involvement in Patients with Metastatic Breast Cancer: Prevalence, Predictive Factors and Impact on Overall Survival","volume":"14","author":"Miller","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaoncol.2021.1359","article-title":"Central Nervous System\u2013Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma","volume":"7","author":"Corbett","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"102924","DOI":"10.1016\/j.esmoop.2024.102924","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases from the Randomized DESTINY-Breast03 Trial","volume":"9","author":"Hurvitz","year":"2024","journal-title":"ESMO Open"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41523-023-00592-5","article-title":"Incidence of HER2-Expressing Brain Metastases in Patients with HER2-Null Breast Cancer: A Matched Case Analysis","volume":"9","author":"Moss","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"PD13-07","DOI":"10.1158\/1538-7445.SABCS20-PD13-07","article-title":"Abstract PD13-07: Subgroup Analysis of Patients with Brain Metastases from the Phase 3 ASCENT Study of Sacituzumab Govitecan versus Chemotherapy in Metastatic Triple-Negative Breast Cancer","volume":"81","author":"Weaver","year":"2021","journal-title":"Cancer Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41571-025-01008-y","article-title":"Emerging Importance of HER3 in Tumorigenesis and Cancer Therapy","volume":"22","author":"Garrett","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.2025.43.16_suppl.2005","article-title":"Patritumab Deruxtecan (HER3-DXd) in Active Brain Metastases (BM) from Metastatic Breast (mBC) and Non\u2013Small Cell Lung Cancers (aNSCLC), and Leptomeningeal Disease (LMD) from Advanced Solid Tumors: Results from the TUXEDO-3 Phase II Trial","volume":"43","author":"Preusser","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2024.42.16_suppl.104","article-title":"Sacituzumab Tirumotecan (SKB264\/MK-2870) in Patients (Pts) with Previously Treated Locally Recurrent or Metastatic Triple-Negative Breast Cancer (TNBC): Results from the Phase III OptiTROP-Breast01 Study","volume":"42","author":"Xu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"LB1-06","DOI":"10.1158\/1557-3265.SABCS24-LB1-06","article-title":"Abstract LB1-06: Primary Results of SOLTI VALENTINE: Neoadjuvant Randomized Phase II Trial of HER3-DXd Alone or in Combination with Letrozole for High-Risk Hormone Receptor Positive (HR+)\/HER2-Negative (Neg) Early Breast Cancer (EBC)","volume":"31","author":"Oliveira","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1038\/s41591-025-03734-3","article-title":"Atezolizumab plus Paclitaxel and Bevacizumab as First-Line Treatment of Advanced Triple-Negative Breast Cancer: The ATRACTIB Phase 2 Trial","volume":"31","author":"Gion","year":"2025","journal-title":"Nat. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/j.annonc.2024.08.295","article-title":"347MO The Safety and Efficacy of Ivonescimab in Combination with Chemotherapy as First-Line (1L) Treatment for Triple-Negative Breast Cancer (TNBC)","volume":"35","author":"Ouyang","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/j.annonc.2024.08.1312","article-title":"1255MO A Phase II Safety and Efficacy Study of PM8002\/BNT327 in Combination with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","volume":"35","author":"Wu","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.674","article-title":"607O Interim Results of a Phase I Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors","volume":"35","author":"Oliva","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"PS8-09","DOI":"10.1158\/1557-3265.SABCS24-PS8-09","article-title":"Abstract PS8-09: Zanidatamab in Combination with Evorpacept in HER2-Positive and HER2-Low Metastatic Breast Cancer: Results from a Phase 1b\/2 Study","volume":"31","author":"Montero","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-Macrophage Therapy for HER2-Overexpressing Advanced Solid Tumors: A Phase 1 Trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"ref_184","first-page":"141","article-title":"American Cancer Society Guidelines for Breast Cancer Screening: Update 2003","volume":"53","author":"Smith","year":"2003","journal-title":"CA Cancer J. Clin."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s00330-024-11085-9","article-title":"Interval Breast Cancer Rates for Tomosynthesis vs Mammography Population Screening: A Systematic Review and Meta-Analysis of Prospective Studies","volume":"35","author":"Libesman","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-023-07034-7","article-title":"Head-to-Head Comparison of Contrast-Enhanced Mammography and Contrast-Enhanced MRI for Assessing Pathological Complete Response to Neoadjuvant Therapy in Patients with Breast Cancer: A Meta-Analysis","volume":"202","author":"Kaiyin","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0140-6736(25)00582-3","article-title":"Comparison of Supplemental Breast Cancer Imaging Techniques-Interim Results from the BRAID Randomised Controlled Trial","volume":"405","author":"Gilbert","year":"2025","journal-title":"Lancet"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2589-7500(24)00267-X","article-title":"Screening Performance and Characteristics of Breast Cancer Detected in the Mammography Screening with Artificial Intelligence Trial (MASAI): A Randomised, Controlled, Parallel-Group, Non-Inferiority, Single-Blinded, Screening Accuracy Study","volume":"7","author":"Josefsson","year":"2025","journal-title":"Lancet Digit. Health"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T05:16:59Z","timestamp":1767158219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":188,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["curroncol33010015"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33010015","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2025,12,27]]}}}